Cargando…

Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats

BACKGROUND: Avitinib is one type of the third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer (NSCLC) with EGFR mutations. The purpose of this study was to investigate the effect of avitinib on the pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Qingjun, Jiang, Hui, Wang, Shuanghu, Dai, Dapeng, Chen, Feifei, Meng, Deru, Geng, Peiwu, Tong, Hongfeng, Zhou, Yunfang, Pan, Debiao, Zhou, Quan, Wang, Chunjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529555/ https://www.ncbi.nlm.nih.gov/pubmed/32812378 http://dx.doi.org/10.1111/1759-7714.13587

Ejemplares similares

Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats
por: Shi, Yong, et al.
Publicado: (2021)

In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine
por: Chen, Feifei, et al.
Publicado: (2020)

Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo
por: Zhou, Yunfang, et al.
Publicado: (2020)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
por: Wang, Shuanghu, et al.
Publicado: (2023)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method
por: Wang, Jinhui, et al.
Publicado: (2021)

Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
por: Xu, Jia, et al.
Publicado: (2023)

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS
por: Wang, Bo, et al.
Publicado: (2020)

Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS
por: Xia, Mengming, et al.
Publicado: (2023)

Inhibitory Effect of Lygodium Root on the Cytochrome P450 3A Enzyme in vitro and in vivo
por: Zhou, Yunfang, et al.
Publicado: (2020)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023)

Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo
por: Wang, Yiran, et al.
Publicado: (2022)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
por: Wang, Li, et al.
Publicado: (2022)

Polymorphic mutations in the polb gene promoter and their impact on transcriptional activity
por: Wu, Qingjun, et al.
Publicado: (2022)

Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer
por: Zhou, Yunfang, et al.
Publicado: (2017)

Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance
por: Wang, Shuanghu, et al.
Publicado: (2017)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

Determination and pharmacokinetic study of AZD‐3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer
por: Wu, Qingjun, et al.
Publicado: (2018)

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study
por: Yuan, Zheng, et al.
Publicado: (2022)

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects
por: Zhang, Qing, et al.
Publicado: (2023)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

An UPLC-MS/MS Method for Determination of Osimertinib in Rat Plasma: Application to Investigating the Effect of Ginsenoside Rg3 on the Pharmacokinetics of Osimertinib
por: Ying, Zhenzhen, et al.
Publicado: (2020)

Pharmacokinetics and Bioavailability Study of Tubeimoside I in ICR Mice by UPLC-MS/MS
por: Chen, Lianguo, et al.
Publicado: (2018)

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
por: Xu, Caihua, et al.
Publicado: (2020)

A stepwise-targeting strategy for the treatment of cerebral ischemic stroke
por: Hu, Jingbo, et al.
Publicado: (2021)

Retraction Note to: A stepwise-targeting strategy for the treatment of cerebral ischemic stroke
por: Hu, Jingbo, et al.
Publicado: (2022)

Study on In Vitro Metabolism and In Vivo Pharmacokinetics of Beauvericin
por: Yuan, Yu, et al.
Publicado: (2022)

Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
por: Xu, Xiao
Publicado: (2015)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats
por: Dong, Song-Tao, et al.
Publicado: (2018)

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight
por: Fujiwara, Yutaka, et al.
Publicado: (2023)

Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells
por: Hu, Lulu, et al.
Publicado: (2023)

Two polymorphic mutations in promoter region of DNA polymerase β in relatively higher percentage of thymic hyperplasia patients
por: Wu, Qingjun, et al.
Publicado: (2020)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_88bsjinpmusrh9rcc7lptli654